Recursion's stock has been consistently rated as "Hold" by this analyst due to skepticism about its AI-driven drug discovery approach and its financial instability. The company's IPO raised over $500 ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

As many veteran investors can attest, biotech stocks are tricky to trade. Their potential upside is enormous, but so is their risk. Too many of these names end up being complete busts. If you pick the ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...